Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
Torsten Dahlén(Karolinska University Hospital), Leif Stenke(Karolinska University Hospital), Ulla Olsson‐Strömberg(Uppsala University Hospital), Kristina Myhr‐Eriksson(Sunderby sjukhus), Anders Själander(Umeå University), Arta Dreimane(Linköping University Hospital), Hjalmar Flygt(Uppsala University Hospital), Johan Richter(Skåne University Hospital), Gustaf Edgren(Karolinska University Hospital), Per Ljungman(Karolinska University Hospital), Hans Wadenvik, Jingcheng Zhao(Karolinska Institutet), Martin Höglund(Uppsala University)
Cited by 15
Related Papers
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
|New England Journal of Medicine|2017|1.2k
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
|Blood|2013|632
Thalassemia Syndromes
|Unknown|2009|475